However, our lab has reported that early postoperative increases in interleukin‐6 (IL‐6) are associated with an increased risk for loss of fixation.(65) Therefore, future work is needed to determine whether IL‐6, which also contributes to insulin resistance and hyperglycemia,(66) contributes to implant related outcomes in T2DM. The gene discussed is IL6; the disease is Hyperglycemia.